Arctoris was featured in a Drug Discovery World (DDW) webinar discussing how automated experimentation platforms can accelerate drug discovery, particularly during urgent global health challenges such as the COVID-19 pandemic.
The presentation highlights how automated laboratory workflows can enable scientists to rapidly generate high-quality experimental data while maintaining reproducibility and scalability. By integrating robotics, automated liquid handling, and advanced analytical tools, such platforms help researchers test hypotheses and evaluate drug candidates more efficiently.
In response to the COVID-19 crisis, the Arctoris team demonstrated the speed and flexibility of the Ulysses® automated drug discovery platform by onboarding and validating multiple critical assays targeting key viral processes, including those responsible for viral replication and infectivity. These assays were implemented and validated in less than 24 hours, enabling researchers to rapidly begin evaluating potential therapeutic compounds.
The webinar also discusses how automated experimentation improves the quality of experimental data and supports faster decision-making in drug discovery programs. By generating consistent and well-annotated datasets at scale, automated platforms help scientists assess molecular candidates with greater confidence and speed, an important advantage during rapidly evolving public health emergencies.
The session features Dr. Daniel Thomas, Head of Discovery Biology at Arctoris, who discusses case studies demonstrating how automation can support the rapid testing of new hypotheses and accelerate the discovery of potential treatments.
